Glioma vaccine development is hindered by tumor heterogeneity and immune evasion mechanisms, including upregulation of PD‐L1, secretion of immunosuppressive cytokines, and recruitment of regulatory T cells. This complexity necessitates innovative strategies to overcome barriers to vaccine efficacy. This evidence concerns the gene CD274 and glioma.